TGFB1 and B-cell chronic lymphocytic leukemia: Targeting of some of these non-canonical pathways (e.g., PI3K) is established in the B-cell malignancy chronic lymphocytic leukaemia (CLL); however, the relevant contribution of autocrine or paracrine TGFB signalling in this cascade is unclear [24].